Key Takeaways
- Revenue fell 22% YoY, a sharp miss: Q2 FY27 revenue dropped to ~₹507 crores as development work dried up, vitamin D analog sales declined, and biotech customers deferred orders into the next financial year because funding was diverted to AI companies.
- Fixed-cost structure magnified the pain: EBITDA collapsed to ~₹46 crores because most expenses are fixed; management expects the same leverage to work in reverse when revenue recovers.
- The H2 recovery story is back-loaded and fragile: Deferred orders, vitamin D analog uplift, and early-phase pipeline rebuilding are all expected to land in H2, but management already concedes FY27 will not show growth over last year.
- Bavla and tech transfers are the medium-term thesis: Management guided Bavla revenue in excess of ₹400–450 crores next financial year and flagged a big pharma tech transfer worth CHF 1.5–2 crore annually, but both depend on regulatory timelines and customer readiness.
- What to watch next quarter: Whether the deferred Q1/Q2 orders actually ship in H2, whether early-phase development work rebounds as biotech funding returns, and whether the ECB drawdown closes before year-end to start reducing interest costs.
The Revenue Shortfall: What Broke and Why
- Development revenue dried up in August and September: Orders expected to complete by end-September did not materialize, and some were deferred to the next financial year because customers lacked funding.
- Biotech funding was diverted to AI: Capital that biotech companies counted on to advance molecules was redirected to AI ventures, creating a bubble that starved early-phase CDMO work. Management described early-phase development as "kind of dry" compared to Phase III.
- Vitamin D analogs, the most profitable sub-segment, declined: The Marketable Molecules segment fell to ₹118 crores from ₹143 crores YoY, driven by lower Calcifediol and Calcitriol sales, which also compressed margins in Q2 and H1.
- Drug product business also contracted: A third leg of the revenue decline came from the drug product business, compounding the CDMO and Marketable Molecules softness.
- The Japanese customer's timing shifted: Last year, a large portion of revenue from the Japanese customer arrived in H1; this year, much of it is expected in H2, depending on the customer's stock position and order timing.
- Swiss business faces structural cost pressure: Carbogen Amcis historically focused on biotech, small scale, and niche products, but price competition is intense because Swiss-based costs are far higher than other regions.
Dalal: "It was obviously an unusual quarter for us. But what we saw was that the revenues that we could accrue in terms of the development work, especially in August and September, those were quite low, as compared to what our expectation was. And this was because certain orders, which we were expecting could be completed by the end of September, they were not. And because of the customer requirements, some of them were also deferred to the next year because of the funding situation."
Margin Impact: Fixed Costs Meet Falling Revenue
- CDMO margin halved: Q2 FY27 CDMO margin fell to 12.3% from 25% YoY; H1 margin fell to 8.7% from 21% YoY, driven almost entirely by the revenue decline against a largely fixed cost base.
- EBITDA dropped to ~₹46 crores: Management emphasized that most expenses are fixed in nature, so the revenue decline had a disproportionate impact, and expects the reverse leverage as revenues increase.
- Other expenses fell 23% YoY: The ~₹105 crore figure reflects some cost-control measures implemented across the Group to ensure appropriate profitability on customer molecules.
- Full-year operating profit will be lower vs. last year: Management stated it may not be able to match last year's operating margin and declined to provide a specific figure when an analyst asked if ~₹500 crores was realistic.
- Marketable Molecules margin also suffered: The decline in vitamin D analogs, the most profitable sub-segment, dragged down segment-level margins in both Q2 and H1.
Dalal: "Since most of our expenses are fixed in nature, the decline in the revenue would have a significant impact on the EBITDA. And on the flip side, as the revenues increase in the future, that should also have a significant positive impact on the EBITDA."
The H2 Recovery Bet
- Deferred orders from Q1 still await shipment: Orders pushed from Q1 to H2 remain in the book; some orders expected to ship in Q2 may now slip to the next financial year, but management insists they are not lost.
- Vitamin D analogs expected to pick up in H2: The cholesterol business dominated H1 within Marketable Molecules; the higher-margin vitamin D analog business is expected to rebound in the second half.
- Both early-phase and Phase III revenues expected to increase in H2: Management anticipates the pickup will carry into the next financial year as biotech funding returns and big pharma targeting gains traction.
- Inventories represent production awaiting shipment: The increase in inventories reflects production done for orders where shipments have not yet happened; these are expected to go out in the remaining two quarters.
- Full-year FY27 revenue will not grow: Management explicitly guided that the current financial year may not show growth over last year, but expects to get closer to that number by year-end.
- The funding environment is showing early signs of recovery: Management noted funding is now coming back to biotech, which should help increase the pipeline of early-phase molecules, and expects improvement over coming months.
Fritschi: "ur consideration is if AI development continues slowing down, some shift of venture capital into pharmaceutical industry is expected. This means more new API development projects will be funded, what leads into an increased demand of CDMO services. So, let's see what happens, but we are rather optimistic here."
Tech Transfers and Bavla: The Medium-Term Pivot
- Two Carbogen Amcis legacy products are being transferred to India: The first, involving an American company, has been successfully initiated and remains on schedule for completion by the end of this financial year; the second technology transfer is currently underway.
- A big pharma tech transfer carries CHF 15–2 crore annual revenue potential: Validation batches are expected around March-April; pilot runs and tech transfer are ongoing with the client closely involved, and management said there is "nothing to be expected as a surprise at the moment."
- Bavla revenue guided at ₹400–450 crores next financial year: This depends on completion of technology transfers and a promising big pharma project for KSM/intermediates.
- Overall annualized tech transfer revenue potential: roughly CHF 25–3 crore: This is a ballpark figure, subject to contract negotiation, spanning multiple ongoing transfers including about three commercial, two intermediates, and Key Starting Material.
- The Swiss-India strategy is taking shape: The Swiss entity will focus on its core strength of developing extremely niche complex molecules, while India will do larger-scale manufacturing; multiple tech transfers are in the pipeline, though regulatory filing changes mean it takes time.
- Nine senior Carbogen Amcis Europe staff are visiting India sites: Over four weeks, they are supporting technology transfer, customer engagement, and harmonizing systems across project management, R&D, sales, and EHS.
Fritschi: "his specific tech transfer I was referring to is from a big pharma. And it's quite significant, as Harshil mentioned, something between CHF 15 and 2 crore revenues to be expected once it's transferred. So, the tech transfer itself follows the normal procedure. There's nothing to be expected as a surprise at the moment."
Strategic Shifts: Big Phrma, Early Phase, and Commercial Expansion
- The company is now targeting big pharma for development: Historically focused on biotech small molecules, management is now pursuing big pharma, especially Phase III molecules, with the intent to do commercial manufacturing out of India sites.
- Early-phase gap is being addressed: Over the past year-plus, the company was busy with late-phase and commercial production, leaving no capacity for early phase; strategy and sales force have now been adjusted to tackle early phase.
- Three more commercial products were added this calendar year: Existing commercial products also saw increased order income as customers who had previously overstocked now need more.
- Naroda secured its first commercial contract for a macrocyclic peptide: This follows product market approval in July 2026 and supports a U.S. market launch.
- A semiconductor project could reach several 100 metric tons: After months of collaboration between Carbogen Amcis Switzerland and DCAL India, the customer requested a quotation for an initial volume of several 100 metric tons.
- U.S. commercial team is expanding: The U.S.-based chief commercial officer visited India in late September to explore opportunities to strengthen global teams; additional revenue and orders are expected from the U.S. market in short time.
- South American market showing early successes: Attempts to conquer the South American market are yielding new customers and orders.
- A second co-investment with the Japanese innovator is expected to go live next financial year: The customer received approval for first-line treatment, which is a factor for uplift in outlook, and the co-investment will provide increased capacities.
Dalal: "he business is dependent upon one, the molecules coming for development. And historically, what we have been targeting are the small molecules, so essentially the biotech company. But now as Stephan alluded, we are also now trying to target the big pharma also on the development side, especially the molecules in Phase III as well, with a very clear idea that we could do the commercial manufacturing out of the India sites."
Balance Sheet, Funding, and the Family Transaction
- ECB drawdown is nearing completion: The final piece of drawing down ECB funds is being completed; management is trying to finish before Christmas holidays, otherwise in the new calendar year. The first drawdown is at least close to about 5 crore.
- Interest costs should start declining soon: Management expects interest costs to come down as soon as the ECB is deployed, most likely from Q4, otherwise from Q1 of next financial year.
- NCDs were raised for refinancing and maintenance Capex: No other fresh fundraising is being done.
- Working capital shortened on lower receivables and payables: The decrease in trade receivables is largely on account of lower revenues vs. March 31; the decrease in payables includes a decrease in advances from the Japanese customer as cash is deployed for co-investment.
- The funding transaction process is in its final stages: After shareholders' approval, steps including share transfers and settlement between family members were completed; condition precedents are now being finalized and tax opinions obtained, with multi-jurisdictional law firms and banks involved.
- Management denied the family agreement distracted from performance: When asked if the overhang affected execution, management stated, "There is no bearing on the financial performance of the company."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year FY27 revenue | Do not expect growth over last year; expect to get closer to that number by year-end | FY27 |
| Full-year FY27 operating profit | Will be lower vs. last year; may not match last year's operating margin | FY27 |
| Full-year FY27 Capex | Close to ~₹200 crores, including maintenance Capex and SAP/digital transformation | FY27 |
| Bavla full-year revenue | In excess of ₹400–450 crores | Next financial year (FY28) |
| Medium-term top-line growth | At least high-single-digit or double-digit growth; 10–12% yearly for FY28-29 | Medium term / FY28-29 |
| Medium-term EBITDA margin | In excess of 20–21% | FY28-29 |
| ECB first tranche drawdown | At least close to ~₹5 crore; trying to complete before Christmas holidays, otherwise January | Q4 FY27 or Q1 FY28 |
| Interest cost reduction | As soon as ECB is deployed; most likely from Q4, otherwise Q1 next financial year | Q4 FY27 or Q1 FY28 |
| Big pharma tech transfer validation | Validation batches expected around March-April | Around March-April |
| First Carbogen Amcis legacy product tech transfer | On schedule for completion by end of this financial year | FY27 |
| Second co-investment with Japanese innovator | Expected to go live, providing increased capacities | Next financial year (FY28) |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹507 cr, 22% decline YoY |
| Cost of goods sold | ₹34 cr, ~7% of revenue, similar to last year |
| Employee expenses | ₹321 cr |
| Other expenses | ₹105 cr, 23% decline YoY |
| EBITDA | ₹46 cr |
| H1 FY27 EBITDA | ₹106 cr |
| Depreciation | ₹90 cr; H1 FY27: ₹181 cr |
| Finance cost | ₹40 cr |
| CDMO segment revenue | ₹388 cr, vs ₹509 cr in Q2 FY26 |
| CDMO segment margin | 12.3%, vs 25% in Q2 FY26 |
| Marketable Molecules segment revenue | ₹118 cr, vs ₹143 cr in Q2 FY26 |
| CapEx | $5.4 million; H1 FY27: $10.3 million |
| Full-year FY27 CapEx guidance | ~₹200 cr |
| Full-year FY27 revenue guidance | Might not see growth vs FY26, revised from high single-digit growth |
| Full-year FY27 consolidated EBITDA margin guidance | 15–16% |
| Development pipeline | CHF 9.8 cr, up from CHF 8.9 cr in Q1 FY27 |
| Late Phase III pipeline | ~13 molecules, up from 10 six months ago; one molecule commercialized in calendar year |
| Net debt (consolidated) | ~₹16.5 cr |
| Cash balance | ~₹1,000 cr |
| French facility revenue | CHF 0.1 cr |
| French facility EBITDA | Negative CHF 0.17 cr |
| Bavla full-year revenue expectation (next financial year) | In excess of ₹400–450 cr |
| Medium-term annual revenue growth expectation | At least high-single digit or double-digit |
| Medium-term EBITDA margin expectation | In excess of 20–21% for FY28-29 |
| Expected quarterly interest cost post-ECB deployment | ₹20–25 cr, down from current ~₹40 cr |
| Annualized revenue potential from ongoing tech transfers | Roughly CHF 2.5–3 cr (per management's ballpark assumption, stated as CHF 3 cr or CHF 25 to 3 cr) |